Drug Regulatory Affairs and the CTD

In short: The Common Technical Document (CTD) gives regulatory applications for human medicines a shared structure. This guide explains what each module contains and how regulatory affairs teams coordinate the dossier while accounting for regional requirements.

Role of regulatory affairs

Regulatory affairs teams coordinate information needed for product applications and communications with health authorities. They work with quality, manufacturing, nonclinical and clinical teams to assemble evidence, check that summaries match the detailed reports, and maintain a clear view of requirements for each market.

The CTD helps organise that information. It describes where information belongs in a dossier; it does not decide which studies or data are required for a particular product or application. Those requirements depend on the applicable authority and submission type. The ICH M4(R4) guideline organises applications for human pharmaceuticals into five modules; Module 1 holds region-specific information and is not itself part of the harmonised CTD, which covers Modules 2–5.

The five CTD modules

ICH M4(R4) intends Modules 2–5 to use a common structure across regions. Module 1 contains regional information, and its content and format can be set by the relevant authority. A dossier therefore needs to follow both the CTD organisation and the current instructions for the market where the application is made.

Preparing a well-organised dossier

Start by identifying the product, application type and target market. Check the authority’s current submission instructions, then map each document to the appropriate module and section. Keep the summaries in Module 2 aligned with the supporting quality, nonclinical and clinical material in Modules 3, 4 and 5.

Example in-house criterion: Use clear document names, accurate tables of contents and working cross-references. Confirm that each document is complete and that its version is consistent wherever it is referenced. These are practical document-control steps; they do not replace the authority’s requirements for the application.

For related background, see clinical trial terminology, clinical trials, and the ICH Q10 pharmaceutical quality system.

Frequently asked questions

Does the CTD specify which studies are required?

No. ICH M4(R4) sets out how information is organised. It does not prescribe the studies needed for an application. Check the requirements that apply to the product and submission type.

Which CTD modules are common across regions?

Modules 2, 3, 4 and 5 are intended to follow a common structure. Module 1 is region-specific and may contain local administrative and prescribing information.

What belongs in Module 2?

Module 2 contains the dossier summaries and overviews. These summarise the quality, nonclinical and clinical information presented in the supporting modules.

References

• International Council for Harmonisation (ICH). Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use, ICH Harmonised Guideline M4(R4), current Step 4 version dated 15 June 2016. Official guideline PDF.
• International Council for Harmonisation (ICH). M4: The Common Technical Document official overview page. ICH CTD page.